AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24635006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation individualized activity intervention
Number of subjects: 71
Study 22453568 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 36 months
Number of subjects: 200
Study 22453568 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 12 months
Number of subjects: 200
Study 20569786 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care PCIT (PC‐PCIT)
Number of subjects: 30
Study 20569786 — intervention group
Group type: COMPARATOR
Intervention: PCIT Anticipatory Guidance (PCIT‐AG)
Number of subjects: 30
Study 17042738 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) 20 microg/day
Number of subjects: 53
Study 17042738 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (ALN) 10 mg/day
Number of subjects: 53
Study 14730238 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg)
Number of subjects: 40
Study 14730238 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (400 mg)
Number of subjects: 40
Study 11701727 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved glycemic control (IC)
Number of subjects: 43
Study 11701727 — intervention group
Group type: COMPARATOR
Intervention: Usual glycemic control (UC)
Number of subjects: 43
Study 9308742 — intervention group
Group type: EXPERIMENTAL
Intervention: Short prophylaxis with low molecular weight heparin (LMWH) during hospitalisation
Number of subjects: 198
Study 9308742 — intervention group
Group type: COMPARATOR
Intervention: Prolonged prophylaxis with low molecular weight heparin (LMWH) for three weeks after hospitalisation
Number of subjects: 198
Study 9308742 — intervention group
Group type: EXPERIMENTAL
Intervention: Short prophylaxis with low molecular weight heparin (LMWH)
Number of subjects: 198
Study 7701033 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone, 25 mg orally
Number of subjects: 11
Study 7701033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7701033 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 11
Study 3661052 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (1.0 mg)
Number of subjects: 10
Study 3661052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortolone (20 mg)
Number of subjects: 10
Study 3661052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (80 mg)
Number of subjects: 10
Study 3661052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31689641 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-MTM
Number of subjects: 32
Study 31689641 — intervention group
Group type: COMPARATOR
Intervention: SMC
Number of subjects: 32
Study 28731780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine chip (CHX) in addition to scaling and root planing (SRP)
Number of subjects: 120
Study 28731780 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric chip in addition to scaling and root planing (SRP)
Number of subjects: 120
Study 28731780 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 120
Study 26413749 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg daily oral spironolactone for 12 weeks
Number of subjects: 86
Study 26413749 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 12 weeks
Number of subjects: 86
Study 23444322 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based administration of the STOFHLA
Number of subjects: 80
Study 23444322 — intervention group
Group type: COMPARATOR
Intervention: Paper-based administration of the STOFHLA
Number of subjects: 80
Study 22335183 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with medical management
Number of subjects: 200
Study 22335183 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling intervention
Number of subjects: 200
Study 22335183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of naltrexone and brief counseling
Number of subjects: 200
Study 22335183 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard tuberculosis treatment without alcohol intervention)
Number of subjects: 200
Study 19726350 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension with isoflurane (1%-2%) and sodium nitroprusside (0.3-3 microg.kg(-1).min(-1))
Number of subjects: 30
Study 19726350 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension with isoflurane (1%-2%) and glonoin (0.5-5 microg.kg(-1).min(-1))
Number of subjects: 30
Study 19726350 — intervention group
Group type: COMPARATOR
Intervention: Routine general anesthesia (group A)
Number of subjects: 30
Study 17474559 — intervention group
Group type: EXPERIMENTAL
Intervention: predilution hemodiafiltration (HDF)
Number of subjects: 13
Study 17474559 — intervention group
Group type: COMPARATOR
Intervention: low-flux hemodialysis (HD)
Number of subjects: 13
Study 15911473 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto (study medication)
Number of subjects: 1
Study 15911473 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 1
Study 12038493 — intervention group
Group type: EXPERIMENTAL
Intervention: Common lures containing constituents from bizarre target items
Number of subjects: 0
Study 12038493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bizarre lures containing constituents from common target items
Number of subjects: 0
Study 12038493 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased verbal elaboration
Number of subjects: 0
Study 10367023 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training programs
Number of subjects: 25
Study 10367023 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training programs
Number of subjects: 25
Study 10367023 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 25
Study 7564452 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits
Number of subjects: 30
Study 7564452 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuits
Number of subjects: 30
Study 2202239 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental drug
Number of subjects: 0
Study 2202239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7018165 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural estrogen (estradiol‐17 beta 4 mg + estriol 2 mg/norethisterone acetate 3 mg per tablet)
Number of subjects: 111
Study 7018165 — intervention group
Group type: COMPARATOR
Intervention: Artificial estrogen (ethinyl estradiol 50 micrograms/ norethisterone acetate 3 mg per tablet)
Number of subjects: 111
Study 31438790 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Release surgery with Dexamethasone injection
Number of subjects: 65
Study 31438790 — intervention group
Group type: COMPARATOR
Intervention: Carpal Tunnel Release surgery alone
Number of subjects: 65
Study 28656463 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WB-MRI) parameters including signal fat fraction (sFF) and apparent diffusion coefficient (ADC)
Number of subjects: 21
Study 28656463 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WB-MRI) parameters
Number of subjects: 21
Study 25574939 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to social support sections plus gaming
Number of subjects: 157
Study 25574939 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to social support features
Number of subjects: 157
Study 25574939 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to both social support features and gaming
Number of subjects: 157
Study 25574939 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to social support sections
Number of subjects: 157
Study 25574939 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to gaming experience
Number of subjects: 157
Study 25574939 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified experience
Number of subjects: 157
Study 25574939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to the website)
Number of subjects: 157
Study 23652893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal cream (Promiseb® Topical Cream); applied topically twice daily for up to 14 days
Number of subjects: 42
Study 23652893 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream; applied topically twice daily for up to 14 days
Number of subjects: 42
Study 23652893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal cream
Number of subjects: 42
Study 23652893 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 42
Study 23652893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 42
Study 21856230 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 μg)
Number of subjects: 1506
Study 21856230 — intervention group
Group type: COMPARATOR
Intervention: Daily recombinant FSH (rFSH) (200 IU)
Number of subjects: 1506
Study 19565745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee-needle therapy
Number of subjects: 150
Study 19565745 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture with fire-cupping or warm needle moxibustion
Number of subjects: 150
Study 17448376 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP-guided therapy (goal of decreasing BNP plasma levels <100 pg/ml)
Number of subjects: 220
Study 17448376 — intervention group
Group type: COMPARATOR
Intervention: Clinical group (medical treatment according to current guidelines)
Number of subjects: 220
Study 15334509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI); 28 days of twice-daily inhalation followed by 28 days off for 56 weeks
Number of subjects: 184
Study 15334509 — intervention group
Group type: COMPARATOR
Intervention: Routine subject management (control group)
Number of subjects: 184
Study 11568032 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic calcium channel blocker therapy (CCCBT) continued with diltiazem (120 mg/d) for 5 years
Number of subjects: 120
Study 11568032 — intervention group
Group type: COMPARATOR
Intervention: Suspension of chronic calcium channel blocker therapy (CCCBT)
Number of subjects: 120
Study 9613738 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1800 mg/day)
Number of subjects: 20
Study 9613738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8086868 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula
Number of subjects: 758
Study 8086868 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 758
Study 8086868 — intervention group
Group type: COMPARATOR
Intervention: Donor breast milk
Number of subjects: 758
Study 8086868 — intervention group
Group type: COMPARATOR
Intervention: Mother's milk
Number of subjects: 758
Study 2199619 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (60 weeks)
Number of subjects: 646
Study 2199619 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 646
Study 686545 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced disulfiram treatment (methadone contingent upon disulfiram ingestion)
Number of subjects: 0
Study 686545 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients urged to take disulfiram but received methadone regardless)
Number of subjects: 0
Study 30640250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-Bowman blunt keratectomy (EBK)
Number of subjects: 22
Study 30640250 — intervention group
Group type: COMPARATOR
Intervention: Diluted ethanol (EtOH)
Number of subjects: 22
Study 27686569 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling surgery (tension-free vaginal tape)
Number of subjects: 176
Study 25526229 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS)
Number of subjects: 0
Study 25526229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22509011 — intervention group
Group type: EXPERIMENTAL
Intervention: Western culture individuals
Number of subjects: 30
Study 22509011 — intervention group
Group type: EXPERIMENTAL
Intervention: Eastern culture individuals
Number of subjects: 30
Study 21197512 — intervention group
Group type: COMPARATOR
Intervention: HS + LA (2% lidocaine in 0.2 ml)
Number of subjects: 12
Study 21197512 — intervention group
Group type: COMPARATOR
Intervention: HS + ketorolac (3 mg in 0.2 mL)
Number of subjects: 12
Study 21197512 — intervention group
Group type: COMPARATOR
Intervention: HS alone (control)
Number of subjects: 12
Study 18295556 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel preparation 1
Number of subjects: 24
Study 18295556 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel preparation 2
Number of subjects: 24
Study 18295556 — intervention group
Group type: EXPERIMENTAL
Intervention: Method validation
Number of subjects: 24
Study 15761294 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to x rays
Number of subjects: 0
Study 14512675 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFE system (Xillix Technologies)
Number of subjects: 332
Study 14512675 — intervention group
Group type: COMPARATOR
Intervention: D-light system (Storz)
Number of subjects: 332
Study 14512675 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFE system
Number of subjects: 332
Study 14512675 — intervention group
Group type: COMPARATOR
Intervention: D-light system
Number of subjects: 332
Study 10389780 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided CVC placement
Number of subjects: 145
Study 10389780 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-TEE guided)
Number of subjects: 145
Study 8778554 — intervention group
Group type: EXPERIMENTAL
Intervention: Eleutherococcus senticosus Maxim L (ESML)
Number of subjects: 20
Study 8778554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 1667345 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (LAVV)
Number of subjects: 46
Study 1667345 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 46
Study 6360936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg daily (group A)
Number of subjects: 50
Study 6360936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg daily (group B)
Number of subjects: 50
Study 6360936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 50
Study 31813866 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aspirin gel
Number of subjects: 30
Study 31813866 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aspirin mouthwash
Number of subjects: 30
Study 31813866 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 30
Study 29523415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (1200 mg/day)
Number of subjects: 1460
Study 29523415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (high plasma level group ≥1637 ng/mL)
Number of subjects: 1460
Study 29523415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (low plasma level group)
Number of subjects: 1460
Study 29523415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1460
Study 26672686 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT screening strategy
Number of subjects: 399
Study 26672686 — intervention group
Group type: COMPARATOR
Intervention: Limited screening strategy
Number of subjects: 399
Study 24163120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg once daily for 6 weeks)
Number of subjects: 83
Study 24163120 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (40 mg once daily for 6 weeks)
Number of subjects: 83
Study 22810568 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhemchuzhnaya‐complex protection toothpaste
Number of subjects: 0
Study 22810568 — intervention group
Group type: EXPERIMENTAL
Intervention: Noviy zhemchug ftor toothpaste
Number of subjects: 0
Study 22810568 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhemchug svezhaya myata toothpaste
Number of subjects: 0
Study 22810568 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20606658 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine 75 mg q.h.s. for 4 weeks
Number of subjects: 43
Study 17416907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg kg‐1
Number of subjects: 68
Study 17416907 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.5 mg kg‐1
Number of subjects: 68
Study 17416907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg kg‐1
Number of subjects: 68
Study 16784365 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families Program (intervention)
Number of subjects: 0
Study 16784365 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 15276659 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 37.5 mg
Number of subjects: 544
Study 15276659 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg
Number of subjects: 544
Study 15276659 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 150 mg
Number of subjects: 544
Study 15276659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 15276659 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 544
Study 10720128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial Radiation Therapy (CRT)
Number of subjects: 222
Study 10720128 — intervention group
Group type: COMPARATOR
Intervention: No Cranial Radiation Therapy (CRT-)
Number of subjects: 222
Study 8965154 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (2 liters of a nutritive amino acid solution containing approximately 2.25 g/liter lysine‐glutamate and 2.50 g/liter arginine)
Number of subjects: 80
Study 8965154 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 80
Study 8965154 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 80
Study 1389189 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg of nitroglycerin
Number of subjects: 30
Study 1389189 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms/kg of nitroglycerin
Number of subjects: 30
Study 1389189 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 4008387 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin + Gentamicin
Number of subjects: 0
Study 4008387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin + Gentamicin
Number of subjects: 0
Study 4008387 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin + Gentamicin
Number of subjects: 0
Study 4008387 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin
Number of subjects: 0
Study 4008387 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 0
Study 4008387 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin
Number of subjects: 0
Study 31280997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (200 mg/kg per hour for the first 8 hours, followed by 100 mg/kg per hour for another 16 hours, same dose for another 24 hours)
Number of subjects: 30
Study 31280997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no N-acetylcysteine)
Number of subjects: 30
Study 30942658 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Target group (received individual AQM data compared to target AQM goals)
Number of subjects: 0
Study 30942658 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Comparison group (received information on individual AQM data compared to average performance of residents)
Number of subjects: 0
Study 30942658 — intervention group
Group type: COMPARATOR
Intervention: Control group (received an email with contact information of a population health coordinator and a list of AQMs)
Number of subjects: 0
Study 28745035 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-resorbable d‐PTFE titanium‐reinforced membranes (Group A)
Number of subjects: 40
Study 28745035 — intervention group
Group type: COMPARATOR
Intervention: Titanium meshes covered by cross‐linked collagen membranes (Group B)
Number of subjects: 40
Study 28745035 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study 26466684 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line antidepressant minimum dosing strategy
Number of subjects: 0
Study 26466684 — intervention group
Group type: COMPARATOR
Intervention: First-line antidepressant maximum dosing strategy
Number of subjects: 0
Study 26466684 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line antidepressant continuation strategy
Number of subjects: 0
Study 26466684 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line antidepressant augmentation strategy
Number of subjects: 0
Study 26466684 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line antidepressant switching strategy
Number of subjects: 0
Study 23387504 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week yoga intervention
Number of subjects: 51
Study 21411151 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL chlorhexidine (CHX) application
Number of subjects: 145
Study 21411151 — intervention group
Group type: COMPARATOR
Intervention: Control (no swab)
Number of subjects: 145
Study 19644062 — intervention group
Group type: EXPERIMENTAL
Intervention: TRPM7 gene variation (16 tag-SNPs)
Number of subjects: 490
Study 17700131 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour I device treatment (one treatment in abdomen, thighs, or flanks)
Number of subjects: 164
Study 17700131 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 164
Study 17700131 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety monitoring (laboratory testing, pulse oximetry, liver ultrasound)
Number of subjects: 164
Study 15499438 — intervention group
Group type: COMPARATOR
Intervention: WHO-17D and Brazilian 17DD yellow fever vaccines
Number of subjects: 1087
Study 11509308 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary rehabilitation service
Number of subjects: 140
Study 11509308 — intervention group
Group type: COMPARATOR
Intervention: Geriatric day-hospital care
Number of subjects: 140
Study 9747404 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance therapy
Number of subjects: 74